Optimisation of ADMET Properties: Past, Present and Future
Role of Hepatic Drug Metabolism in Early Preclinical Profiling
Course Tutor: Constance Höfer
These pre-conference training courses are being held prior to the ADMET Europe conference.
Morning Course - Part 1 (09:00-12:30)
“Optimisation of ADMET properties: past, present and future”
This course analyses the emergence of ADMET as a preclinical discipline, discusses current practices in ADMET optimisation, and looks at how technological innovations combined with R&D strategy changes may impact ADMET practices in pharmaceutical R&D.
Course contents:
- Development of ADMET optimisation as a result of modern drug design strategies
- Overview of current ADMET in vitro/in vivo/in silico techniques and models
- Impact of new technologies on traditional ADMET: in silico prediction models, microdosing, metabolomics
- ADMET in high content vs high throughput environments
This course is aimed primarily at participants without pre-existing in-depth knowledge of the area, and will provide a comprehensive and easily accessible primer to develop a broad understanding of the topics discussed.
This course would be useful for industrial and academic scientists, as well as managers and health professionals wanting to improve their understanding of current and future roles of ADME in drug R&D.
An understanding of biological and chemical principles is assumed, as is familiarity with current concepts in drug research and development.
Afternoon Course - Part 2 (13:30-17:00)
“Role of hepatic drug metabolism in early preclinical profiling”
This course looks at the role of the liver in metabolism vs drug metabolism, its role in drug safety and efficacy, discusses mechanisms and models of hepatic metabolism/hepatotoxicity, and addresses the difficulties in understanding or predicting hepatic drug metabolism /hepatotoxicity in early preclinical stages. Finally, current issues in understanding or predicting Drug induced liver disease will be discussed.
Course Contents:
- Hepatic metabolism vs hepatic drug metabolism: function, mechanisms, models, predictions
- Hepatic (drug) metabolism in drug safety and efficacy
- Impact of reduced hepatic function on drug metabolism
- Drug induced hepatotoxicity: mechanisms, models, implications for tox programmes
- Drug induced liver injury (DILI) modelling/prediction: is it possible?
This course is aimed primarily at participants without pre-existing in-depth knowledge of the area, and will provide a comprehensive and easily accessible primer to develop a broad understanding of the topics discussed.
This course would be useful for industrial and academic scientists, as well as managers and health professionals wanting to improve their understanding of the role of liver metabolism in drug efficacy/drug safety, and of the issues associated with the prediction of drug metabolism/ hepatotoxicity in drug R&D.
An understanding of biological and chemical principles is assumed, as is familiarity with current concepts in drug research and development.